- Qualigen Therapeutics Inc QLGN has submitted an Investigational New Drug (IND) application to the FDA for its QN-165 with an initial target indication of COVID-19 in hospitalized patients.
- QN-165, a DNA aptamer, is a broad-based antiviral drug candidate that has exhibited antiviral activity in multiple in vitro assays against different viruses.
- Price Action: QLGN shares are up 10.1% at $1.96 during the premarket session on the last check Wednesday.
- Related content: Benzinga's Full FDA Calendar.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
